As Hikma prepared for its generic launch, the company realized that Amarin had “carefully and purposely" inked a web of exclusive supplier contracts, the lawsuit says.

Generic drugmaker Hikma Pharmaceuticals USA Inc has sued Amarin Pharma Inc, accusing it of using illegal tactics to delay generic competition for its heart drug Vascepa.

Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing ...

Riad Mishlawi, president of Hikma’s injectables business, has been named CEO. His appointment is effective Sept. 1, 2023. Said Darwazah will step down as acting CEO and return to his role as ...

After Hikma initiated a recall of one batch of acetaminophen injection earlier this month, the company is extending the nationwide recall to the consumer level. The company started the recall (PDF ...

On August 22, 2024, Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals, PLC (collectively Hikma), filed a petition for rehearing en banc, asking the US Court of Appeals for the Federal ...

Summary. Hikma Pharmaceuticals is a FTSE 250 generic drug manufacturer that was founded in the Middle East in 1978. The company has many attractive features, including a long track record of ...

Hikma's branded generic will compete with Teva Pharmaceuticals (TEVA.TA), opens new tab authorized generic of Victoza in the United States that was launched earlier this year.

Hikma will benefit from 180 days of exclusivity in the U.S. generic market upon launch, the company added. More on Hikma Pharmaceuticals, Novartis, etc.

Hikma set out plans last year to boost cash returns to shareholders. If approved at today’s AGM, the company will pay a final dividend of 47 cents (37.6p) per share, ...

Hikma Pharmaceuticals was fined $4,400 by the Ohio EPA for hazardous waste violations. The company shipped a mislabeled tote of corrosive cleaning chemical to a facility unauthorized to handle ...

Generic drugmaker Hikma Pharmaceuticals USA Inc has sued Amarin Pharma Inc, accusing it of using illegal tactics to delay generic competition for its heart drug Vascepa. In a complaint filed ...